Literature DB >> 30190913

A surgical perspective report on melanoma management.

Brian D Wernick1,1, Neha Goel2,2, Francis Sw Zih2,2, Jeffrey M Farma2,2.   

Abstract

Management of melanoma includes wide excision with adequate margins and lymph node biopsy depending on the depth of the lesion, with subsequent completion lymphadenectomy for positive sentinel node. Locally advanced disease can be approached in several different ways depending on a variety of patient and disease-specific factors. These include surgical resection, isolated limb perfusion and infusion and intralesional injection therapy such as talimogene laherparepvec, IL-2 and Bacille Calmette-Guerin. Ongoing controversy exists regarding the utility of completion lymphadenectomy, and trials such as MSLT-2 will attempt to shed light on this issue. The future of melanoma management will likely focus on expanding the use of immunotherapy, allowing for narrower surgical margins, particularly in sensitive anatomic areas, and limiting the number of completion lymphadenectomies.

Entities:  

Keywords:  T-VEC; completion lymphadenectomy; in-transit disease; intralesional injection therapy; isolated limb infusion; isolated limb perfusion; melanoma; melanoma in situ; melanoma margins; sentinel lymph node biopsy

Year:  2017        PMID: 30190913      PMCID: PMC6094622          DOI: 10.2217/mmt-2016-0031

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  37 in total

1.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

2.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Authors:  Wendy R Cornett; Linda M McCall; Rebecca P Petersen; Merrick I Ross; Henry A Briele; R Dirk Noyes; Jeffrey J Sussman; William G Kraybill; John M Kane; H Richard Alexander; Jeffrey E Lee; Paul F Mansfield; James F Pingpank; David J Winchester; Richard L White; Vijaya Chadaram; James E Herndon; Douglas L Fraker; Douglas S Tyler
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

3.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

4.  Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm.

Authors:  G Cohn-Cedermark; L E Rutqvist; R Andersson; M Breivald; C Ingvar; H Johansson; P E Jönsson; L Krysander; C Lindholm; U Ringborg
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

Review 5.  Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.

Authors:  Hidde M Kroon; Anna M Huismans; Peter C A Kam; John F Thompson
Journal:  J Surg Oncol       Date:  2014-03       Impact factor: 3.454

6.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

7.  Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.

Authors:  Georgia M Beasley; Paul Speicher; Ketan Sharma; Hilliard Seigler; April Salama; Paul Mosca; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2013-12-24       Impact factor: 6.113

8.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.

Authors:  D Liénard; A M Eggermont; H Schraffordt Koops; B B Kroon; F Rosenkaimer; P Autier; F J Lejeune
Journal:  Melanoma Res       Date:  1994-03       Impact factor: 3.599

9.  The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study.

Authors:  Alastair D MacKenzie Ross; Lauren E Haydu; Michael J Quinn; Robyn P M Saw; Kerwin F Shannon; Andrew J Spillane; Jonathan R Stretch; Richard A Scolyer; John F Thompson
Journal:  Ann Surg Oncol       Date:  2015-11-11       Impact factor: 5.344

10.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Authors:  D L Fraker; H R Alexander; M Andrich; S A Rosenberg
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

View more
  1 in total

1.  Impact of Wide Local Excision on Melanoma Patient Survival: A Population-Based Study.

Authors:  Alessandra Buja; Massimo Rugge; Giovanni Damiani; Giuseppe De Luca; Manuel Zorzi; Riccardo Fusinato; Chiara De Toni; Antonella Vecchiato; Paolo Del Fiore; Francesca Falasco; Romina Spina; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Front Public Health       Date:  2022-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.